CUE Biopharma

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Oct. 04, 2022 — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells directly within the patientís body, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CUE-101, its lead clinical…
40 Guest Street Boston, MA 02135

617-949-2680